Evidence map›Paper›PMID 36680006›Full record

ReviewVaccines2023

Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management.

Vivek P Chavda, Pankti Balar, Dixa Vaghela, Hetvi K Solanki, Akta Vaishnav, Vivek Hala, Lalitkumar Vora

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Vivek P ChavdaDepartment of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
Pankti BalarPharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.ORCID 0000-0002-5718-669X
Dixa VaghelaPharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.ORCID 0000-0003-3129-6468
Hetvi K SolankiPharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
Akta VaishnavPharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
Vivek HalaPharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.ORCID 0000-0002-6300-168X
Lalitkumar VoraSchool of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.ORCID 0000-0001-8106-9066
B.J. Medical College · INQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omicron variants have highly influenced the entire globe. It has a high rate of transmissibility, which makes its management tedious. There are various subtypes of omicron, namely BA.1, BA.2, BA.3, BA.4, and BA.5. Currently, one omicron subvariant BF.7 is also immersed in some parts of India. Further studies are required for a better understanding of the new immersing SARS-CoV-2 subvariant of the omicron. They differ in the mutation of the spike proteins, which alters their attachment to the host receptor and hence modifies their virulence and adaptability. Delta variants have a great disastrous influence on the entire world, especially in India. While overcoming it, another mutant catches the pace. The Indian population is highly affected by omicron variants. It alters the entire management and diagnosis system against COVID-19. It demanded forcemeat in the health care system, both qualitatively and quantitively, to cope with the omicron wave. The alteration in spike protein, which is the major target of vaccines, leads to varied immunization against the subvariants. The efficacy of vaccines against the new variant was questioned. Every vaccine had a different shielding effect on the new variant. The hesitancy of vaccination was a prevalent factor in India that might have contributed to its outbreak. The prevalence of omicron, monkeypox, and tomato flu shared some similarities and distinct features when compared to their influence on the Indian population. This review emphasizes the changes omicron brings with it and how the Indian health care system outrage this dangerous variant.

Indexed as

diagnosishesitancyIndiamonkeypoxomicrontomato fluvaccination

Identifiers

PMID36680006
PMCPMC9860853
OpenAlexW4315781554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.